The phase 1/2 ARROW study enrolled 233 patients with locally advanced or metastatic solid RET fusion-positive NSCLC to treat with 400 mg once-daily oral pralsetinib (7). The gene discussed is RET; the disease is non-small cell lung carcinoma.